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BACKGROUND: There is increasing evidence that high-risk human papilloma virus (HPV) is involved in cancers in addition to cervical
cancer. For example, it is generally accepted that HPV has a role in a significant proportion of head and neck tumours, and it has long
been hypothesised that hormone dependent oncogenic viruses, such as HPV may have causal roles in some human breast cancers.
A number of reports have identified HPV DNA in breast tissue and breast cancer specimens, but these rely on standard polymerase
chain reaction (PCR), which is criticised for its propensity for contamination.
METHODS: We have used two different technologies, in situ and standard PCR (with sequencing), and histology based on light
microscopy.
RESULTS: We unambiguously demonstrate the presence of high-risk HPV in the cells of breast cancer specimens and breast cancer cell
lines. In addition, we also show that the oncogenic characteristics of HPV associated breast cancer are very similar to HPV-associated
cervical cancer. Specifically, that putative koilocytes are present in some HPV associated breast cancers.
INTERPRETATION: The above observations indicate a likely causal role for high-risk HPV in human breast cancer and offer the possibility
of primary prevention of some breast cancers by vaccination against HPV.
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Although the association of human papilloma virus (HPV) with
cervical cancer, and head and neck cancers is well established, the
involvement of the virus in breast cancer is more controversial.
Previous studies have demonstrated the presence of HPV high-risk
types 16, 18 and 33 in breast cancer specimens from diverse
populations around the world: Italy, Norway, China, Japan, USA,
Austria, Brazil, Australia, Taiwan, Turkey, Greece, Korea, Mexico,
Hungary and Syria (Lonardo et al, 1992; Hennig et al, 1999; Yu
et al, 1999; Liu et al, 2001; Damin et al, 2004; Widschwendter et al,
2004; de Villiers et al, 2005; Kan et al, 2005; Tsai et al, 2005; Gumus
et al, 2006; Kroupis et al, 2006; Lawson et al, 2006; Choi et al, 2007;
Akil et al, 2008; Khan et al, 2008; Kulka et al, 2008; Mendizabal-
Ruiz et al, 2009). The prevalence of HPV positive breast cancer in
these studies was reported to vary from 4% in Mexican to 86%
in American women. In all studies, high-risk HPV was found in
tumour tissue only and not in surrounding normal tissue, with the
exception of the study from Turkey, in which the virus was
also detected in normal tissue but at a lower level than in the
cancer (Gumus et al, 2006). Although the route of transmission
for the virus has not been determined, women positive for
both breast and cervical cancers were found to be infected with
the same HPV type in both tumours (Hennig et al, 1999;
Widschwendter et al, 2004).
The controversy surrounding the role of HPV in breast cancer
may be because of the difficulty that has been encountered in
detecting the virus in breast specimens, in contrast to the relative
ease of detection in cervical cancers (Lindel et al, 2007; Khan et al,
2008). Indeed, in a previous study from our group, we demon-
strated that it was necessary to use SYBR Green I (Molecular
Probes, Carlsbad, CA, USA) for polymerase chain reaction (PCR)
detection of virus in breast cancer in DNA extracted from breast
tissue (Kan et al, 2005). This is considered to be because of the
fact that a considerable proportion of breast cancer specimens is
non-cancerous and that the levels of virus are low in breast cancer.
One solution to the detection of such low levels of HPV is the use
of in situ PCR.
The oncogenic mechanisms by which HPV induces cervical
cancer have been intensively studied (zur Hausen, 2002). In this
study, we have used HPV-associated cervical cancer as a model.
High-risk HPV encodes a series of proteins, designated as early
(E1–E7) or late (L1 and L2). Although all of the viral proteins have
a role in viral replication, only a small number of the viral early
proteins have a role in cellular transformation. Key to transforma-
tion are the E6 and E7 oncoproteins, which work in concert to
disrupt cell-cycle regulation, inhibit apoptosis and stimulate cell-
cycle progression by binding/inhibiting the p53 and p110
RB
tumour suppressor genes, respectively. In addition, and relevant
to this study, HPV E5 and E6 act early in transformation (before
integration) and are known to disrupt cytokeratin causing
perinuclear cytoplasmic clearing and nuclear enlargement, which
leads to the appearance of a koilocyte (Krawczyk et al, 2008;
Thomison et al, 2008).
If HPV is oncogenic in human breast cancer, we hypothesise
that high-risk HPV should be present in (some) human breast
cancers and in some normal and pre-cancerous tissue (although at
a lower proportion), and that koilocytosis should be apparent in
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sHPV-associated breast cancers, and that HPV will be detected in
some proportion of breast cancer cell lines.
In this paper we report on the presence of HPV in breast cancer
cell lines, in the nuclei of cells within the cancerous regions of
breast cancer specimens and correlate the presence of HPV with
the histopathological features of HPV-induced transformation.
MATERIALS and METHODS
Archival specimens
Unselected formalin-fixed breast cancer specimens and non-
cancer specimens from women who had breast reduction surgery,
were analysed using in situ PCR. All the specimens were from
women living in Australia. A total of 28 breast cancer specimens
and 28 unselected non-cancerous breast specimens were suitable
for use in this in situ PCR study. Fifteen of the fixed specimens
were ductal carcinoma in situ (dcis) and 13 were predominantly
invasive ductal carcinomas (idc).
Breast cancer cell lines
Standard PCR techniques were used to determine if HPV DNA
genetic material was present in the human breast cancer cell lines:
MCF-7, T47D, BT-549, HBL-100, Hs578.T, MDA-MB-453, MDA-
MB-468, MDA-MB-175-VII and SK-BR-3.
In situ PCR
Four-micron thick sections of breast tumour tissue were cut and
placed on silanised slides. Positive controls (known virus-positive
cervical cancer tissue), and negative controls (known virus-
negative tissue), and controls omitting DIG-11-dUTP (to confirm
incorporation of DIG label), omitting primers (to confirm the
signal was the result of specific amplification rather than self
priming of degraded tissues), or omitting Taq polymerase, were
also undertaken for each specimen. The primers used for HPV
in situ PCR for the L1 region of HPV-16 and HPV-18 were forward
(50-GCMCAGGGWCATAAYAATGG-30) and reverse (50-CGTCCM
ARRGGAWACTGATC-30). The outcomes were assessed by the
staining of the DIG label in the tissues by light microscopy.
A number of specimens gave a false-positive signal when the
primers were omitted. The use of exo-zap, initial filling in with
Klenow, and doing two rounds of PCR – the first with no DIG-11-
dUTP and the second with DIG-11-dUTP – gave the same false-
positive results with these particular specimens. Consequently,
we carried out a (no-primer) negative control for each sample at
the same time as the in situ screening PCR and eliminated the
specimens that gave false-positive colour signals. Any specimens
that produced a signal in the in situ PCR negative controls
(omission of the DNA primers and separately, omission of the Taq
polymerase) were eliminated from the study. False positives
indicated that the DNA was self-priming and were unsuitable for
in situ work (this is probably because of fragmented DNA, caused
by formalin fixation, acting as primers). In addition, tissues were
screened by in situ PCR for b-globin to confirm their suitability
for this study.
To confirm the validity of the outcomes of in situ PCR analyses,
DNA was extracted from the same formalin-fixed specimens and
standard PCR analyses were conducted. The methods used are
outlined below. The products were sequenced and the identity of
the sequences was determined using the BLAST alignment system.
Standard PCR
Genomic DNA preparation Previously described protocols were
used to extract genomic DNA from the breast cancer specimens
(Dawkins et al, 1993). The DNA quality was tested by the
amplification of a 268-bp fragment of the b-globin gene using
HotStarTaq DNA polymerase (Qiagen, Dusseldorf, Germany)
and primers G073 (50-GAAGAGCCAAGGACAGGTAC-30) and
G074 (50-CAACTTCATCCACGTTCACC-30). The cycling condi-
tions were 951C for 9min; followed by 35 cycles of 951C, 30s; 551C,
30s; 721C, 1min; and a final extension at 721C, 10min. The
amplified products were visualised on 2% agarose gel.
Screening for HPV sequences Standard PCR was carried out in a
total volume of 50ml using HotStarTaq DNA polymerase (Qiagen)
with the following conditions: 951C for 9min; followed by 35 cycles
of 951C, 30s; 551C, 40s; 721C, 40s; and a final extension at 721C,
10min. Cell lines were screened using the MY/GP HPV consensus
primers as described by Kroupis et al (2006), omission of the
DNA template was used as a negative control. Both MY and GP
primers sets amplify the L1 region of the HPV genome and are
used as a preliminary step for HPV screening. The amplified
products were visualised on a 1.5% agarose gel and sequenced to
confirm the type of HPV. The PCR was independently repeated for
each sample.
Histology
The presence of koilocytosis in the fixed breast cancer series was
assessed by light microscopy with koilocyte positive cervical
cancer specimens used for comparison. Koilocytes were best
characterised by (Koss and Durfee, 1956) the presence of large cells
with relatively small, but irregular and hyperchromatic nuclei
surrounded by clear and transparent cytoplasm. Koilocytosis is
restricted to the replicating basal cells and multinucleation is
common in these cells. The histological features of HPV positive
breast tumours are similar to cervical koilocytosis and have
previously been reported by de Villiers et al (2005).
RESULTS
Breast cancer cell lines
In this study, we demonstrate the application of in situ PCR to
identify HPV sequences within breast cancer cells. We initially
screened nine breast cancer cell lines (as listed in Materials and
Methods) for HPV in situ PCR. High-risk HPV gene sequences
were identified in two of the cell lines (MDA-MB-175-VII and
SK-BR-3) of the nine lines tested. In situ PCR demonstrated
that HPV DNA was confined within the nucleus of the cells
(Figure 1). The presence and type (HPV type 18) was confirmed by
automated sequencing (Figure 2) of the PCR products shown in
Figure 3.
Identification of HPV DNA sequences in formalin-fixed
breast cancer specimens by in situ PCR and sequencing
Having established the method and demonstrated the presence of
HPV in breast cancer cell lines, we screened a series of fixed breast
cancer and normal breast tissue specimens using in situ PCR. As
discussed in Materials and Methods section, we eliminated those
samples, which potentially could give false-positive HPV results,
identified by positive in situ PCR without primers. An unknown
number of these eliminated specimens would have been true
positives. Accordingly, the data cannot be used to make estimates
of prevalence of the presence of these viruses.
High-risk HPV DNA sequences were identified in the nuclei of
breast cancer epithelial cells in 5 (39%) of 13 dcis and 3 (23%) of
13 idc breast cancer specimens (Figure 4, summarised in Table 1).
Unexpectedly, we saw HPV containing cells in the surrounding
normal tissue of some samples (Figure 4D). In all 3 (18%) of 17
normal breast specimens (from breast reduction surgery) were
HPV positive by in situ PCR (Table 1). The presence of HPV in
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sFigure 1 Human papilloma virus (HPV) in situ polymerase chain reaction (PCR) of breast cancer cell lines. (A–C) Cell line MBA-MB-175V11, (D–F) cell
lines BR-SK3 and (G–I) cell lines HeLa (HPV-18 containing cervical cancer cell line: positive control). (A, D and G) In situ PCR with HPV E6 primers.







HeLa   TTTAACAATATGTGCTTCTACACAGTCTCCTGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTT 
       *** ***  ****************** ********* * ********************* ********** * ***** * 
Spec 7.AAATATGTCATTATGTGCTGCCATATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGG 
Figure 2 Polymerase chain reaction (PCR) product nucleotide sequences of human papilloma virus (HPV)-positive patient samples and breast cancer cell
lines. Four HPV-positive breast cancer samples were identified in Figure 4 below (specimens 2, 4, 5 and 6) and two breast cancer cell lines (SK-BR3 and
MDA-MB-175) were identified as HPV type 18, whereas one breast cancer specimen (specimen 7) was identified as HPV type 16. Minor sequence
variations were observed in three samples (specimens 2, 4 and 6) and in both cell lines (SK-BR and MDA-MB-175) when matched against reference
sequence HPV-18 positive HeLa. There is no sequence variation in specimen 7 when matched against HPV-type 16 genome (accession FJ006723).
M
140 bp 214 bp
75/65 bp
11 10 9 8 7 6 5 4 3 2 1
Figure 3 Human papilloma virus (HPV) screen of patient samples using MY and GP primers. Lane M is the Puc/Hinf ladder marker. Lanes 1–7 are
patient samples (breast cancer specimens 1–7). Lane 8 is HeLa DNA as the positive control. Lanes 9–11 are negative controls (water in place of DNA in
reaction). Lanes 2 (specimen 2), 4 (specimen 4), 5 (specimen 5), 6 (specimen 6) and 7 (specimen 7) show positive bands of 140bp. Both samples in lanes 1
(specimen 1) and 3 (specimen 3) are negative for HPV.
HPV associated breast cancer
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snormal breast tissues is consistent with the requirement for HPV
infection in the breast tissue before HPV-induced tumourigenic
transformation of a single clone.
Seven breast cancer specimens and three normal specimens
showed false-positive outcomes when the PCR primer was omitted
from the in situ PCR analysis. These specimens were not
considered further.
Confirmation of in situ PCR analyses
Deoxyribonucleic acid was extracted from the HPV-positive
specimens and analysed by standard PCR (Figure 3) to confirm
the findings based on in situ PCR and to type the HPV by
sequencing (Figure 2). Not all gels and sequences are shown in
Figures 2 and 3. The outcome was confirmed in all the three HPV-
Figure 4 Human papilloma virus (HPV) in cancer cells of ductal carcinoma in situ breast cancer demonstrated by in situ polymerase chain reaction (PCR)
(same specimen in all panels). (A and B) No primer in situ PCR control ( 20 and  40 objective, respectively), (C and D) HPV L1 primer in situ PCR
( 20 and  40 objective, respectively), Dark purple stain in panels A–D indicated amplification of HPV L1 sequences by in situ PCR. (E and F)
Haematoxylin and eosin stain ( 20,  40 objective, respectively). The appearance of koilocytes in the HPV-18 containing cells shown in panel F (selected
koilocytes shown by arrows) is indicated by the clearing of the cytoplasm and condensed, hyperchromatic nuclei.
Table 1 In situ PCR screening for HPV in fixed breast tissue specimens and breast cancer cell lines
Number analysed









Ductal carcinoma in situ 13 5 (39) 5 5 (39)
Invasive ductal carcinoma 13 3 (21) 2 1 3 (21)
Normal breast tissue 17 3 (18) 3 3 (18)
Breast cancer lines 9 2 (22) 2 2 (22)
Abbreviations: HPV¼human papilloma virus; PCR¼polymerase chain reaction.
HPV associated breast cancer
B Heng et al
1348




















spositive normal breast specimens. The outcome was confirmed in
five of the eight HPV-positive breast cancer specimens. Minor
sequence variations indicate that contamination was unlikely.
All HPVs were type 18 except for one specimen in which HPV
was type 16. The identification of two HPV types is a further
indication that contamination is unlikely. Known HPV-positive
(cervical cancer specimens and HeLa cervical cancer cultured cells)
and negative (no PCR primers) were used as controls. All controls
gave the expected outcomes.
HPV-associated morphological characteristics
The features of koilocytosis were observed in 18 (66%) of 28 breast
cancer specimens (Figure 4). Koilocyte-like cells were also
observed in some HPV-positive normal breast tissue specimens.
The koilocyte-like cells were all HPV positive as shown by in situ
PCR. These features are very similar to koilocytosis present in
HPV-positive cervical cancer.
DISCUSSION
In this report, we have confirmed the presence of HPV in the
nuclei of cells in breast cancer tissue. The use of in situ PCR
localises the HPV to the nuclei of cells within the cancerous tissue,
and substantially decreases the possibility that detection of HPV in
breast cancer is a contamination. In addition, the detection of
HPV was consistent with the cell morphology and standard
PCR/sequencing results.
The detection of HPV in breast cancer is consistent with 15 (of 17)
previous publications reporting the presence of HPV in breast
cancer world-wide with a prevalence of ranging from 4–86%
(Lawson et al, 2006). Given such a high proportion of studies
reporting HPV in breast cancer and breast tissue, the question is
why some (2 of 17) studies report that HPV is not present in breast
cancer. Potential explanations include difficulties in detection due
to low viral load and low frequency of HPV in breast cancers in
some populations. The in situ PCR results demonstrate just how
much non-cancerous tissue is present in breast cancer specimens,
which may explain the difficulty in detection of HPV by standard
PCR (upon DNA extraction from the whole tissue sample).
The observation that HPV type 18 was by far the most common
type in these Australian breast cancers is meaningful as most
breast cancers can be regarded as originating from breast-milk
epithelial cells (despite the historically misleading terminology
of ‘ductal’ breast carcinomas). Therefore, most breast cancers are
‘glandular’. HPV type 18 has an affinity or tropism to glandular as
compared with squamous epithelial cells (Clifford and Franceschi,
2008).
It is important to note that we report the presence on high-risk
HPV in normal breast tissue. This supports the previous report of
HPV in normal tissue in Turkish breast samples (Gumus et al,
2006). The presence of HPV in some normal breast samples
(normal breast and normal surrounding breast tissue as shown in
Figure 4) is consistent with a tumourigenic role for HPV in some
breast cancers. If HPV has a causal role in breast cancer, it is
reasonable to expect that this would be an early event, similarly
with cervical cancerogenesis, and that HPV would be found in
at least some normal tissue. Furthermore, it is expected that the
presence of high-risk HPV would not be sufficient for full
tumourigenic transformation and further changes would accumu-
late over time in a step-wise manner.
Significance of these findings
Although the proportion of HPV-positive breast cancer specimens
in this study is higher than HPV-positive normal breast tissues, the
overall number of specimens is small and definitive conclusions
cannot be made. However, given the propensity for HPV to
oncogenically transform human epithelial cells, including breast
epithelial cells (Band et al, 1990), plus the unambiguous evidence
that high-risk HPVs are present in the nuclei of breast cancer cells
and in breast cancer cultured cell lines, and that HPV-positive
koilocytes are present on many normal and breast cancer
specimens, suggests that HPV may have a causal role in many
breast cancers.
Establishing an oncogenic role for HPV in some breast cancers
leads to the possibility of primary prevention of some breast
cancers by vaccination against HPV, as current vaccines are
known to be effective against HPV types 16 and 18 (Rambout et al,
2007).
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